Endocan Levels at Polycystic Ovary Syndrome and Periodontal Inflammation

The Levels of Interleukin-6 and Endocan at Individuals With Polycystic Ovary Syndrome and Periodontal Inflammation

Periodontal diseases are chronic inflammatory disease occurred by the interaction between pathogenic microorganism and the host defense. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with increased risk of cardiovascular events. Endocan is a proteoglycan secreted mainly by endothelial cells under the control of inflammatory cytokines.

Periodontal diseases, including gingivitis, are common chronic infectious diseases caused by predominantly pathogenic microorganisms that colonize the subgingival area and cause local and systemic elevations of proinflammatory cytokines such as Interleukin-6 (IL-6).

Several lines of evidence established the association between periodontal and systemic diseases, including metabolic syndrome, diabetes, and cardiovascular disease.

Because of the fact that both periodontal disease and PCOS are associated with systemic inflammation and insulin resistance, these two disorders may be linked through a common pathophysiologic pathway.

A number of studies have indicated a possible relationship between PCOS and periodontal inflammation. Despite common risk factors, including oxidative stress, the relationship between chronic periodontitis (CP) and PCOS remains unclear.

The aims of the study were to determine serum and saliva Endocan and IL-6 levels and to evaluate the correlation between these two biomarker in women with periodontal disease and PCOS.

Study Overview

• Status: Completed
• Conditions: Polycystic Ovary Syndrome; Cytokines; Inflammation Gum
• Intervention / Treatment: Diagnostic test: Collection of Serum and Saliva Samples

• Study Type: Observational
• Enrollment (Actual): 87

Contacts and Locations

Study Locations

• Turkey
  • Eyalet/Yerleşke
    • İstanbul, Eyalet/Yerleşke, Turkey, 34668
      • Ebru Sağlam

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

All participants were included among women at the Department of Obstetrics and Gynecology, School of Medicine and Department of Periodontology, Faculty of Dentistry , Ataturk University

Description

Inclusion Criteria:

• Newly diagnosed PCOS patients
• Never smokers
• Had no history of systemic disease
• BMI<25 kg/m2
• Participants had ≥20 teeth present.

Exclusion Criteria:

• Pregnancy
• Lactation
• Hemoglobin A1c (HbA1c) ≥ 6.5%
• 2-h oral glucose tolerance test (OGTT-2h) ≥200
• Cushing syndrome, non-classic congenital adrenal hyperplasia, hyperprolactinemia, thyroid dysfunction, and androgen-secreting tumors
• Using antibiotics and antiinflammatory within the past 6 months
• Periodontal treatment within the past 6 months

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group 1; PCOS participants with periodontitis	Diagnostic test: Collection of Serum and Saliva Samples; Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
Group 2; PCOS participants with periodontally healthy	Diagnostic test: Collection of Serum and Saliva Samples; Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
Group 3; systemically healthy participants with periodontitis	Diagnostic test: Collection of Serum and Saliva Samples; Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
Group 4; systemically and periodontally healthy participants	Diagnostic test: Collection of Serum and Saliva Samples; Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum and salivary Endocan levels	Enzyme-Linked Immunosorbent Assay (ELISA)	one year
Serum and salivary interleukin-6 levels	Enzyme-Linked Immunosorbent Assay (ELISA)	one year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical attachment level (CAL)	Periodontal measurement	one year
Probing pocket depth (PD)	Periodontal measurement	one year
Gingival Index	Periodontal measurement	One year

Collaborators and Investigators

• Sponsor: Ebru Saglam
• Collaborators: Ataturk University
• Investigators: Study Director: Ebru Sağlam, PhD, Bezmialem Vakif University; Principal Investigator: Ayşe Toraman, Ataturk University; Principal Investigator: Engin Şebin, Erzurum Regional Training and Research Hospital; Study Chair: Cenk Fatih Çanakçı, Professor, Ataturk University; Principal Investigator: Hümeyra Çanakçı, Dr, Private Practice; Study Director: Metin İngeç, Professor, Ataturk University

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 3, 2017
• Primary Completion (ACTUAL): November 29, 2017
• Study Completion (ACTUAL): November 29, 2017

Study Registration Dates

• First Submitted: August 23, 2017
• First Submitted That Met QC Criteria: August 25, 2017
• First Posted (ACTUAL): August 29, 2017

Study Record Updates

• Last Update Posted (ACTUAL): February 10, 2020
• Last Update Submitted That Met QC Criteria: February 7, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Neoplasms; Endocrine System Diseases; Disease; Ovarian Cysts; Cysts; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Stomatognathic Diseases; Periodontal Diseases; Mouth Diseases; Gingival Diseases; Polycystic Ovary Syndrome; Syndrome; Inflammation; Gingivitis
• Other Study ID Numbers: EbSAGLAM1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No